Pathologies such as inflammatory bowel diseases (IBD) and colorectal cancer (CRC) are characterized by a high activity of GSK3β in epithelial cells and their microenvironment [29,30,31], but the etiology of this over-activity is poorly understood. This evidence concerns the gene GSK3B and inflammatory bowel disease.